Phase II study of high-dose aclarubicin in previously treated patients with small-cell lung cancer.
Jensen
P B
PB
Department of Oncology, University Hospital Rigshospitalet, Copenhagen, Denmark.
Larsen
S K
SK
Stilbo
I
I
D015250:Aclarubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence
D015250:Aclarubicin